Literature DB >> 27179655

Worsening of lipid metabolism after successful treatment of primary aldosteronism.

Christian Adolf1, Evelyn Asbach1, Anna Stephanie Dietz1, Katharina Lang2, Stefanie Hahner2, Marcus Quinkler3, Lars Christian Rump4, Martin Bidlingmaier1, Marcus Treitl5, Roland Ladurner6, Felix Beuschlein1, Martin Reincke7.   

Abstract

Primary aldosteronism (PA) describes the most frequent cause of secondary arterial hypertension. Recently, deterioration of lipid metabolism after adrenalectomy (ADX) for aldosterone-producing adenoma (APA) has been described. We analysed longitudinal changes in lipid profiles in a large prospective cohort of PA patients. Data of 215 consecutive PA patients with APA (n = 144) or bilateral idiopathic adrenal hyperplasia (IHA, n = 71) were extracted from the database of the German Conn's Registry. Patients were investigated before and 1 year after successful treatment by ADX or by mineralocorticoid receptor antagonists (MRA). Glomerular filtration rate (GFR), fasting plasma glucose and components of lipid metabolism including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were determined at 8.00 after a 12-h fasting period. One year after initiation of treatment mean serum potassium levels and blood pressure normalized in the patients. HDL-C and TG developed inversely with decreasing HDL-C levels in patients with APA (p = .046) and IHA (p = .004) and increasing TG levels (APA p = .000; IHA p = .020). BMI remained unchanged and fasting plasma glucose improved in patients with APA (p = .004). Furthermore, there was a significant decrease of GFR in both subgroups at follow-up (p = .000). Changes in HDL-C and TG correlated with decrease in GFR in multivariate analysis (p = .024). Treatment of PA is associated with a deterioration of lipid parameters despite stable BMI and improved fasting plasma glucose and blood pressure. This effect can be explained by renal dysfunction following ADX or MRA therapy.

Entities:  

Keywords:  Aldosterone; Glomerular hyperfiltration; Lipid metabolism; Primary aldosteronism

Mesh:

Substances:

Year:  2016        PMID: 27179655     DOI: 10.1007/s12020-016-0983-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  43 in total

Review 1.  Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis.

Authors:  W Chen; F Li; C He; Y Zhu; W Tan
Journal:  Ir J Med Sci       Date:  2013-08-30       Impact factor: 1.568

2.  Albuminuria in untreated patients with primary aldosteronism or essential hypertension.

Authors:  J M Halimi; A Mimran
Journal:  J Hypertens       Date:  1995-12       Impact factor: 4.844

3.  Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus?

Authors:  J Widimský; B Strauch; G Sindelka; J Skrha
Journal:  Physiol Res       Date:  2001       Impact factor: 1.881

4.  Risk of New-Onset Dyslipidemia After Laparoscopic Adrenalectomy in Patients with Primary Aldosteronism.

Authors:  Mayuko Kaga; Takanobu Utsumi; Tomoaki Tanaka; Takashi Kono; Hidekazu Nagano; Koji Kawamura; Naoto Kamiya; Takashi Imamoto; Naoki Nihei; Yukio Naya; Hiroyoshi Suzuki; Tomohiko Ichikawa
Journal:  World J Surg       Date:  2015-12       Impact factor: 3.352

5.  Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.

Authors:  Gilberta Giacchetti; Vanessa Ronconi; Federica Turchi; Laura Agostinelli; Franco Mantero; Silvia Rilli; Marco Boscaro
Journal:  J Hypertens       Date:  2007-01       Impact factor: 4.844

6.  Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry.

Authors:  M Reincke; C Meisinger; R Holle; M Quinkler; S Hahner; F Beuschlein; M Bidlingmaier; J Seissler; S Endres
Journal:  Horm Metab Res       Date:  2010-01-29       Impact factor: 2.936

Review 7.  Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.

Authors:  N D Vaziri
Journal:  Am J Physiol Renal Physiol       Date:  2006-02

8.  Aldosterone excess impairs first phase insulin secretion in primary aldosteronism.

Authors:  Evelyn Fischer; Christian Adolf; Anna Pallauf; Cornelia Then; Martin Bidlingmaier; Felix Beuschlein; Jochen Seissler; Martin Reincke
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

9.  Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism.

Authors:  A Goldberg; D J Sherrard; J D Brunzell
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

10.  Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study.

Authors:  Joanna Matrozova; Olivier Steichen; Laurence Amar; Sabina Zacharieva; Xavier Jeunemaitre; Pierre-François Plouin
Journal:  Hypertension       Date:  2009-02-16       Impact factor: 10.190

View more
  4 in total

1.  Physiological Aldosterone Concentrations Are Associated with Alterations of Lipid Metabolism: Observations from the General Population.

Authors:  M Hannich; H Wallaschofski; M Nauck; M Reincke; C Adolf; H Völzke; R Rettig; A Hannemann
Journal:  Int J Endocrinol       Date:  2018-03-27       Impact factor: 3.257

2.  Alteration of Gut Microbiota Relates to Metabolic Disorders in Primary Aldosteronism Patients.

Authors:  Yu Liu; Qingyao Jiang; Zhihong Liu; Sikui Shen; Jianzhong Ai; Yuchun Zhu; Liang Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-17       Impact factor: 5.555

3.  The differences of serum lipid profiles between primary aldosteronism and essential hypertension: a meta-analysis and systematic review.

Authors:  Worapaka Manosroi; Pitchaporn Phudphong; Pichitchai Atthakomol; Mattabhorn Phimphilai
Journal:  BMC Endocr Disord       Date:  2022-08-31       Impact factor: 3.263

4.  Systemic pseudohypoaldosteronism-1 with episodic dyslipidemia in a Sudanese child.

Authors:  Asmahan Abdalla; Mohammed Abdulrahman Alhassan; Reem Tawfeeg; Ayman Sanad; Hasan Tawamie; Mohamed Abdullah
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.